Hospital-based Diabetes Prevention Study in Korea
Hospital-based Diabetes Prevention Study in Korea
The investigators will study prevention effect of Life style modification on diabetes
 mellitus comparing with conventional management and Metformin administration.
Inclusion Criteria:

 1. 30<Age<71

 2. BMI≥23 kg/m2

 3. '75g Oral glucose tolerance 2 hours after the test Blood glucose140~199mg/dL' or
 'Fasting Blood Sugar 110~125 mg/dL' or 'HbA1c 5.7%~6.4%'

 Exclusion Criteria:

 1. Who diagnosed with Diabetes Mellitus or Who having Drugs for Diabetes Mellitus.

 2. Type 2 Diabetes Mellitus

 -  Who diagnosed with Diabetes Mellitus except for maternity period.

 -  Who have had drugs for Diabetes Mellitus(hypoglycemic agent or insulin) except
 for maternity period.

 -  Fasting Glucose≥ 126 mg/dL

 -  75g Oral glucose tolerance 2 hours after the Blood glucose ≥ 200 mg/dL

 -  HbA1c ≥ 6.5%

 3. Who life expectancy is short.

 -  Cardiac history

 -  History of severe cardiovascular disease within the last 6 months (cerebral
 hemorrhage, stroke, myocardial infarction, angina pectoris, heart failure,
 etc.)

 -  Systolic blood pressure >180 mmHg or Diastolic blood pressure >105 mmHg

 -  aortic stenosis

 -  Left bundle branch block or Third degree AV block

 -  Who had been diagnosed and treated for malignant tumors including leukemia and
 lymphoma within the last 5 years

 -  Abnormal renal function (Creatinine ≥ 1.4 mg/dL (male) or ≥ 1.3 mg/dL (female) or
 Urine Protein ≥ 2 +)

 -  Anemia(Hematocrit <36%((male) or><33%(female)) ⑤ Cirrhosis or chronic active
 hepatitis (AST/ALT>３UNL)

 -  Acute gastrointestinal disease (pancreatitis, infectious intestinal disease)

 -  Who is scheduled major surgery within the last 3 to 6 months or just after the
 surgery.

 -  Chronic infection (HIV, active tuberculosis, etc.)

 -  Pulmonary patients who rely on oxygen or daily bronchodilators

 4. Who is judged to be able to influence the clinical trial by investigator.

 -  Who can not communicate

 -  Those with psychiatric or cognitive impairment that may affect the compliance of
 the clinical trial

 -  Those who do not agree to the treatment group allocation by random assignment

 -  Those who participate in other studies that may interfere with the clinical trial

 -  Those who lost weight by more than 10% during the past 6 months, excluding weight
 loss after giving birth

 -  Those who can not have normal walking or exercise

 -  Women who are pregnant

 -  Those who are currently pregnant or who are within the last 3 months after giving
 birth

 -  Those planning pregnancy during the clinical trial period

 -  Those who have a history of drug and alcohol abuse (acute, chronic) within the
 last 2 years

 -  Those who are not appropriate or unreliable for clinical trials at the discretion
 of the tester

 5. Who taking medication or medical condition that may affect the diagnosis of diabetes

 -  Thiazide diuretics

 -  Systemic beta blockers

 -  Taking Niacin for the treatment of neutropenic depression

 -  Possibility of taking or injecting a systemic steroid preparation

 -  Taking a serotonin reuptake inhibitor (SSRI) for weight loss purpose.

 -  Taking medicine for weight loss

 -  Hormone status is not appropriate during thyroid hormone replacement therapy (TSH
 abnormal range) (If thyroid hormone therapy is stable for more than 3 months and
 TSH is normal, the patient can participate in)

 -  Others with other endocrine diseases (eg Cushing's syndrome, acromegaly)

 -  During treatment, fasting plasma triglyceride> 600 mg / dL